Thymulin Cuts Age-Linked Inflammation in Mice, Boosting Cancer Immunotherapy
Updated
Updated · Scientific American · Jul 21
Thymulin Cuts Age-Linked Inflammation in Mice, Boosting Cancer Immunotherapy
3 articles · Updated · Scientific American · Jul 21
Summary
Nature Communications published mouse data showing thymulin, a thymus hormone discovered about 50 years ago, reduced age-related inflammation and improved cancer treatment response in older animals.
Higher thymulin levels were linked to myeloid cells producing fewer cytokines, giving researchers a possible mechanism for how the thymus influences inflammaging and longevity.
Older mice with cancer that received thymulin had slower tumor growth and better survival, while also responding more effectively to immunotherapy.
The findings suggest the shrinking thymus may still play a major immune role after puberty and could become a target for therapies against cancer and other age-related inflammatory diseases if confirmed in humans.
Can a forgotten childhood organ hold the key to reversing age-related inflammation and cancer?
This natural hormone fights aging, but with a 10-minute lifespan, can it become a viable human therapy?
Targeting Inflammaging: Thymulin’s Promise for Immune Rejuvenation and Cancer Therapy in Older Adults
Overview
Recent scientific breakthroughs have revealed that thymulin, a natural peptide, plays a crucial role in controlling age-related inflammation and may help boost cancer immunity in older adults. This discovery was made possible by using heterochronic parabiosis, a technique where the blood of young and old mice is shared. Researchers found that older mice experienced reduced inflammation when exposed to younger blood, highlighting thymulin’s potential to reverse some effects of aging. These findings position thymulin as a promising new target for therapies aimed at improving immune function and health outcomes as we age.